Category: antibody

In the fast-paced world of biotechnology, Dr. Kirollos Hanna is making waves with his groundbreaking research on outpatient bispecific antibody delivery. This innovative approach has the potential to transform the landscape of biotech medicine, offering patients a more convenient and cost-effective treatment option. Let’s dive into Dr. Hanna’s compelling argument for outpatient bispecific antibody delivery […]

In the realm of clinical development, the pursuit of novel therapeutic modalities such as bispecific antibodies beckons us to navigate uncharted waters, where strategic acumen is the compass guiding us through the turbulent seas of uncertainty. These innovative biologics, with their dual targeting capabilities, offer a tantalizing promise of heightened efficacy and precision in treating […]

In the realm of cutting-edge biotechnology, a symphony of breakthroughs has recently crescendoed with the remarkable advancements in cancer treatment. Among the pioneering melodies, the harmonious blend of Jazz Pharmaceuticals and Zymeworks Inc. has orchestrated a revolutionary bispecific antibody therapy that has set a new standard in the fight against stomach cancer. Stomach cancer, also […]

In the realm of precision medicine, the emergence of antibody-drug conjugates (ADCs) has revolutionized the therapeutic landscape for HER2-positive breast cancer. This subtype, characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), has historically presented challenges due to its aggressive nature and limited treatment options. However, with the advent of ADCs, such […]

Breast cancer remains a formidable opponent in the realm of oncology, affecting millions of individuals worldwide. While traditional treatments like chemotherapy and surgery have been pivotal in managing the disease, the quest for more targeted and effective therapies continues. Enter antibody-drug conjugates (ADCs), a revolutionary class of bioengineered drugs that combine the specificity of monoclonal […]

In the bustling landscape of biopharmaceutical advancement, innovation is the currency, and at the 17th PEGS Europe Protein & Antibody Engineering Summit, Creative Biolabs didn’t just set up a booth; they orchestrated a symphony of cutting-edge technology. The event served as a stage for Creative Biolabs to unveil a tapestry of updates in antibody discovery, […]

Introduction: Welcome to the intricate world of bispecific antibody therapies, where the promise of targeted treatments is met with the challenge of managing adverse events. In this realm, the delicate balance between therapeutic efficacy and safety is paramount, especially when considering the risk of infections. As bench-to-GMP biotech scientists, we delve into the strategies for […]

Greetings, dear readers! Today, we embark on a fascinating journey into the realm of cutting-edge biopharmaceutical innovations, particularly focusing on the revolutionary impact of novel antibody technologies in the landscape of cancer treatment. Picture a world where the intricate mechanisms of our immune system are harnessed to specifically target and combat cancer cells, offering new […]

Greetings, dear readers! Today, let’s embark on a journey through the fascinating realm of biopharmaceuticals, where groundbreaking changes are afoot. The Food and Drug Administration (FDA) has recently announced a momentous decision that could revolutionize the development and approval process for monoclonal antibody biosimilars. This decision entails the waiver of clinical efficacy studies for certain […]

Greetings, fellow scientific minds! Today, we embark on a riveting journey through the realm of antibody-antigen interactions, delving into the intricate world of affinity and epitope binning. As bench-to-GMP biotech scientists, we are steadfast in our pursuit of unraveling the mysteries of these crucial interactions that underpin the very foundation of immunology and biopharmaceuticals. In […]

In the realm of treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the presence or absence of CD20 expression has emerged as a crucial determinant of patient outcomes when utilizing bispecific antibodies like epcoritamab and glofitamab. Recent real-world analysis has shed light on how the lack of CD20 expression can significantly worsen treatment outcomes […]

In the realm of biotherapeutics, understanding charge heterogeneity is crucial for ensuring product stability, efficacy, and safety. This variability can significantly impact the pharmacokinetics, binding affinity, and biological activity of therapeutic antibodies. Traditionally, methods like two-dimensional gel electrophoresis and ChromiCE have been utilized for characterizing antibody charge variants, but these methods have limitations in terms […]

As the world grapples with the looming threat of infectious diseases, the need for rapid and precise therapeutic solutions has never been more pressing. Traditional methods of identifying and developing antibodies to combat pathogens have been plagued by laborious processes and time constraints, hindering swift responses during public health emergencies. However, a groundbreaking AI-powered technique […]

Monoclonal antibodies have emerged as pivotal therapeutics over the past three decades, revolutionizing the treatment landscape for conditions ranging from cancer to infectious diseases. The market for antibodies surpassed $100 billion globally in 2018, underscoring their significance in healthcare. With the FDA approval of the 100th therapeutic antibody, the importance of selecting antibodies that bind […]

Pfizer and BioNTech have announced groundbreaking results regarding their updated mRNA COVID-19 vaccine for the upcoming 2025-2026 season. This new vaccine formulation has demonstrated a remarkable capability to enhance immune responses, specifically boosting neutralizing antibody levels by a staggering fourfold in older individuals and those with underlying medical conditions. Such promising findings come at a […]

Amgen and Kyowa Kirin are making significant strides in the development of their investigational antibody rocatinlimab for the treatment of atopic dermatitis, a chronic inflammatory skin condition that affects millions worldwide. The partners recently announced positive findings from a Phase III extension study, showcasing the long-term safety and efficacy of rocatinlimab. This development marks a […]

The FDA’s recent decision to waive clinical efficacy studies for a monoclonal antibody biosimilar marks a significant milestone in drug approval processes, offering potential cost reductions and improved patient access to affordable treatments globally. This groundbreaking move eliminates the need for costly and time-consuming clinical efficacy studies (CES) in the approval of biosimilars, particularly for […]

Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment across various cancer types, with both established and emerging agents shaping the landscape of clinical practice. In a recent interview with Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, a nurse practitioner at the Sarah Cannon Research Institute in Nashville, Tennessee, the current and future role of ADCs in breast, bladder, […]

Developing antibody-derived therapeutics hinges on ensuring they are manufacturable, safe, and effective. This article delves into the crucial concept of developability assessment in early-stage discovery, focusing on antibodies and their derivatives like bispecific antibodies and antibody-drug conjugates. By screening properties early on, risks of moving suboptimal candidates to later stages are minimized. With computational tools […]

Akeso Inc has commenced enrollment in a pivotal phase III clinical trial evaluating cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. The COMPASSION-33 study, the third Phase III trial for cadonilimab in gastric cancer, aims to enhance patient outcomes by improving the radical […]

Rozanolixizumab, a humanized IgG4 monoclonal antibody, emerged as a significant advancement in the treatment landscape of myasthenia gravis (MG). Following its initial approval in the US in 2023, this innovative therapy received subsequent approvals in Japan and the European Union by 2025. The pivotal phase 3 MycarinG study (NCT03971422) shed light on the profound effects […]

Virginia researchers have made a significant breakthrough in the fight against sepsis, a life-threatening infection that poses a considerable challenge in the medical field. Led by Jianjie Ma, a professor at the University of Virginia, in collaboration with the University of Michigan, the team has successfully developed a monoclonal antibody designed to halt the progression […]

Mabwell’s innovative CDH17-targeting antibody-drug conjugate, 7MW4911, has received FDA Investigational New Drug (IND) clearance for a Phase 1/2 clinical trial targeting advanced gastrointestinal (GI) cancers, including colorectal cancer. This milestone allows Mabwell to assess the safety, pharmacokinetics, and preliminary efficacy of 7MW4911 in patients with advanced GI tumors, offering a new therapeutic option for a […]

Boehringer Ingelheim has secured FDA accelerated approval for Hernexeos (zongertinib), a groundbreaking kinase inhibitor designed to revolutionize the treatment of a specific subset of non-small cell lung cancer (NSCLC) patients. This approval marks a significant milestone in the fight against lung cancer, particularly for those with unresectable or metastatic NSCLC harboring HER2 (ERBB2) tyrosine kinase […]

High-throughput bio-layer interferometry (BLI) has become a game-changer in the development of new drugs, particularly monoclonal antibodies (mAbs) for clinical trials. Utilizing platforms like Octet from Sartorius, companies like Abveris are able to rapidly identify high-affinity mAbs with specific profiles, a process that was previously time-consuming and uncertain. The efficiency of BLI, which enables real-time […]

Dengue virus (DENV) is a significant public health concern in tropical and subtropical regions, causing severe illness and fatalities. One of the challenges in combating DENV is the phenomenon of antibody-dependent enhancement (ADE), where antibodies from a previous DENV infection can enhance the severity of a subsequent infection with a different serotype. To address this […]

In the realm of relapsed/refractory multiple myeloma (R/R MM) treatment, the recent approval of a third bispecific antibody has sparked a significant shift in the treatment landscape. This approval not only broadens the therapeutic options available but also heightens the competition within the BCMA-targeted therapy space. The new agent has shown promising response rates, particularly […]

Amir Fathi, MD, a prominent leukemia specialist based at Massachusetts General Hospital, emphasizes the significance of collaborative advocacy between patients and their medical team, shedding light on the critical distinctive toxicities that demand careful monitoring post CAR T and bispecific antibody treatments. In the realm of post-treatment surveillance for patients undergoing cutting-edge immunotherapies like chimeric […]